BioSpace News Archive

The Chicago Lighthouse will celebrate the renovation and expansion of its state-of-the-art, fully accessible UI Health Customer Care Center with a special ribbon-cutting ceremony on Wednesday morning, May 8.

MTF Biologics, a leading nonprofit tissue bank dedicated to saving and healing lives, will be featuring its line of placental and dermal wound care innovations at this year’s Symposium on Advanced Wound Care (SAWC) Spring | Wound Health Society Meeting.

TCR2 Therapeutics Inc. (TCR2) (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced online publication of preclinical data in Nature Communications (https://www.nature.com/articles/s41467-019-10097-0).

Plexus Worldwide (Plexus®), a leading direct-selling health and happiness company, is honored to have been named among the Best Places To Work In Direct Selling.

Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at an initial public offering price of $10.00 per share, for gross proceeds of $55 million.

Velocity Urgent Care is pleased to announce its newest walk-in urgent center in Suffolk, Virginia in the Harbour View Marketplace, next to AT&T and Sweet Frog Yogurt at the intersection of Harbour Towne and Hampton Roads Parkways.

Myomo, Inc. announced that it will release its financial results for the first quarter ended March 31, 2019 on Monday, May 13, 2019, before the US markets open.

Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) announced today that Murfreesboro Medical Clinic and SurgiCenter (MMC) has selected 2bPrecise™ to support its precision medicine strategy, beginning with pharmacogenomics (PGx) at the point of care.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2019, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year.